Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-03-27-Speech-4-025"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20030327.1.4-025"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Mr President, I too welcome with great satisfaction the measure being debated today, precisely because it satisfies a series of requirements which are known, I see, to all the MEPs who have decided to discuss it in the Chamber this morning. The first ground for satisfaction is the fact that this report marks a return to research in sectors such as the pharmaceutical sector, where Europe does too little. In my opinion, the Sixth Framework Programme and the resources which have been made available under this programme bear witness to Europe’s desire to commit substantial resources to research in this sector, which not only has economic value but social and political value too. It is not by chance that holding patents and having the possibility to produce medicines and being able to influence their cost, particularly in developing countries, means being able, on the one hand, to press ahead with a development policy for us, and on the other, an aid policy for developing countries.
Many of the Members have stressed how this research, which proposes to help combat diseases by increasing knowledge in order to produce new drugs and to improve existing ones, combines with other policies which we, as Europe, must press ahead with in the education and employment sectors, because education, employment and health are the only factors which can contribute to the achievement of democracy in those countries which see Europe as an increasingly firm point of reference."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples